ALKS Alkermes plc

+0.8  (+4%)
Previous Close 20.85
Open 21
Price To Book 3.12
Market Cap 3,401,877,750
Shares 157,130,612
Volume 944,193
Short Ratio
Av. Daily Volume 1,477,026

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

FDA approval announced July 2, 2018.
Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD)
Phase 3 data due early 2020.
Schizophrenia - young adults
Noted July 15, 2019 that NDA filing due 4Q 2019 will include Bipolar I indication
Schizophrenia, bipolar
CRL received March 15, 2010.
Type 2 diabetes
Approved October 5 2015. sNDA filed for 2-month option with approval announced June 6, 2017.
NDA filing announced December 17, 2018. NDA acceptance announced February 25, 2019. PDUFA estimate December 24, 2019.
Diroximel fumarate (BIIB098)
Multiple sclerosis (MS)
Phase 3 trial did not meet endpoint - February 2017. Second trial is ongoing.
ALKS 6428
Opioid dependence
CRL announced February 1, 2019.
ALKS 5461
Major depressive disorder
Phase 3 preliminary data released June 30, 2017. Primary endpoint met - adverse events included weight gain.
Phase 1/2 data due 2H 2019.
Solid tumors
Phase 3 data released April 9, 2019 - primary endpoint met.
Aristada and Invega Sustenna
Phase 1 initiation announced February 26, 2019.
ALKS 4230 + Keytruda - ARTISTRY-2
Solid tumors
Phase 3 top-line data met primary endpoint - July 30, 2019.
Diroximel fumarate (BIIB098) - Head-to-head trial versus Tecfidera -
Relapsing Remitting Multiple Sclerosis (RRMS)

Latest News

  1. Clovis (CLVS) Q2 Earnings & Sales Lag Estimates, Shares Down
  2. Biotech Stock Roundup: Celgene, Amgen, Gilead Impress in Q2, Other Pipeline Updates
  3. Biogen Hedged Its Bet and Won Big
  4. Diroximel Fumarate Demonstrated Significantly Improved Gastrointestinal Tolerability Profile Compared to Dimethyl Fumarate in Patients with Multiple Sclerosis
  5. Alkermes Announces Settlement With Amneal Over VIVITROL® Patent Dispute
  6. Edited Transcript of ALKS earnings conference call or presentation 25-Jul-19 12:00pm GMT
  7. Alkermes Bounces Back -- but Not Enough
  8. Alkermes (ALKS) Earnings and Sales Beat Estimates in Q2
  9. The Daily Biotech Pulse: Obseva Gets The Greenlight, Verastem Climbs On Licensing Deal, Merit Medical Earnings Disappoint
  10. Alkermes PLC (ALKS) Q2 2019 Earnings Call Transcript
  11. Alkermes (ALKS) Beats Q2 Earnings and Revenue Estimates
  12. The Daily Biotech Pulse: Setback For Bristol-Myers Squibb, Gemphire Explodes, Lilly's Nasal Low Blood Sugar Drug
  13. Alkermes Plc Reports Second Quarter 2019 Financial Results
  14. Alkermes to Host Conference Call to Discuss Second Quarter 2019 Financial Results
  15. Does Alkermes plc (NASDAQ:ALKS) Have A Particularly Volatile Share Price?
  16. Earnings Preview: Alkermes (ALKS) Q2 Earnings Expected to Decline
  17. Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study
  18. ALXN or ALKS: Which Is the Better Value Stock Right Now?
  19. Alkermes to Include Bipolar I Disorder in ALKS 3831 NDA